Characteristics of and current treatment options for hepatitis B and hepatitis C.
Adams
P
P
University of Western Ontario, London, Ont. padams@julian.uwo.ca
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D004338:Drug Combinations; D006509:Hepatitis B / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D004338:Drug Combinations; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D012254:Ribavirin